Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is set to benefit fromtheir strong financial position as they continue to invest in research and development and expanding their international presence through direct sales and acquisitions. AtriCure is actively targeting a growing market for their open ablation treatment, with the potential to significantly increase their revenue and market share by 2030. The company is also positioned to benefit from new quality measures and the STS Star rating system, which could expand their treatment of pre-operative AF cases. Despite facing industry risks, AtriCure's strong financial position and consistent growth plans make them a recommended "buy" alongside other successful medical technology companies.

Bears say

AtriCure is a Buy based on its strong potential upside and profitability in the core business, driven by the growth in open-heart surgery and its AtriClip and Open Ablation franchise. There is also potential for contribution from new verticals like cryoablation. With a price target of $45 based on a 3x revenue estimate, there is significant opportunity for growth and a positive outlook for the company despite risks such as competition and shifts in market share.

AtriCure (ATRC) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 7 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.